Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 29 for:    stem cell peripheral arterial disease | ( Map: United States )

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease (NICE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03743636
Recruitment Status : Recruiting
First Posted : November 16, 2018
Last Update Posted : November 16, 2018
Sponsor:
Collaborator:
American Heart Association
Information provided by (Responsible Party):
Mary McDermott, Northwestern University

Brief Summary:

NICE is a randomized clinical trial that will examine the effects of nicotinamide riboside (NR) both with and without resveratrol to test whether, among people with PAD, NR significantly improves walking performance more than placebo and whether NR combined with resveratrol significantly improves walking performance more than placebo. If our findings support our hypotheses, results will be used to design a large, definitive randomized clinical.

We will randomize 90 participants with PAD to one of the following three groups: NR + resveratrol, NR + placebo, or placebo + placebo. Our primary outcome is change in six-minute walk distance between baseline and 6-month follow-up. Secondary outcomes are change in maximal treadmill walking time, patient-reported walking ability (measured by the Walking Impairment Questionnaire (WIQ)), quality of life (measured by the Short Form-36 Physical Functioning (SF-36 PF) score), and physical activity (measured by accelerometer). Calf skeletal muscle biopsy specimens collected in participants in the NICE Trial will be analyzed for NAD+ abundance, stem cell (satellite cell) abundance and muscle fiber phenotype.


Condition or disease Intervention/treatment Phase
Peripheral Artery Disease Drug: Nicotinamide riboside Drug: Resveratrol Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease: The NICE Trial
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Nicotinamide riboside + resveratrol
Participants randomized to the NR + resveratrol arm of the study will receive 1,000 mg of NR and 125 mg of reservatrol daily for six months.
Drug: Nicotinamide riboside
Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
Other Names:
  • NR
  • Niagen

Drug: Resveratrol
Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.

Active Comparator: Nicotinamide riboside + placebo
Participants randomized to the NR + placebo arm of the study will receive 1,000 mg of NR and a placebo daily for six months.
Drug: Nicotinamide riboside
Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
Other Names:
  • NR
  • Niagen

Other: Placebo
Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.

Placebo Comparator: Placebo + placebo
Participants randomized to the placebo + placebo arm of study will receive placebo pills.
Other: Placebo
Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.




Primary Outcome Measures :
  1. Six-minute walk distance (NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR alone improves six-minute walk distance at 6-month follow-up, compared to placebo.

  2. Six-minute walk distance (NR/resveratrol vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR combined with resveratrol improves six-minute walk performance at 6-month follow-up, compared to placebo.


Secondary Outcome Measures :
  1. Maximal treadmill walking time (NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR alone improves maximal treadmill walking time at 6-month follow-up, compared to placebo.

  2. Walking Impairment Questionnaire (WIQ) distance score (NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR alone improves the WIQ distance score at 6-month follow-up, compared to placebo.

  3. Maximal treadmill walking time (NR/resveratrol vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR combined with resveratrol improves maximal treadmill walking time at 6-month follow-up, compared to placebo.

  4. Walking Impairment Questionnaire (WIQ) distance score (NR/resveratrol vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR combined with resveratrol improves the WIQ distance score at 6-month follow-up, compared to placebo.

  5. Calf muscle changes (increased satellite cell abundance) [ Time Frame: Baseline to 6-month follow-up ]
    We will perform calf muscle biopsies to determine whether among participants with PAD, those randomized to NR + resveratrol and NR alone haveincreased satellite cell abundance compared to the placebo group.

  6. Calf muscle changes (NAD+ abundance) [ Time Frame: Baseline to 6-month follow-up ]
    We will perform calf muscle biopsies to determine whether among participants with PAD, those randomized to NR + resveratrol and NR alone have increased calf muscle NAD+ abundance, compared to the placebo group.

  7. Calf muscle changes (improved muscle fiber phenotype) [ Time Frame: Baseline to 6-month follow-up ]
    We will perform calf muscle biopsies to determine whether among participants with PAD, those randomized to NR + resveratrol and NR alone have improved muscle fiber phenotype, compared to the placebo group.

  8. Six-minute walk distance (NR/Resveratrol or NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in six-minute walk distance, compared to those randomized to placebo.

  9. Maximal treadmill walking time (NR/resveratrol or NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in maximal treadmill walking time, compared to those randomized to placebo.

  10. Walking Impairment Questionnaire (WIQ) distance score (NR/resveratrol or NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in WIQ distance score, compared to those randomized to placebo.

  11. Physical Activity (NR/resveratrol or NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in physical activity, compared to those randomized to placebo.

  12. NAD+ Abundance (NR/resveratrol or NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in NAD+ abundance, compared to those randomized to placebo.

  13. Satellite Cell Abundance (NR/resveratrol or NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in satellite cell abundance, compared to those randomized to placebo.

  14. Muscle Fiber Phenotype(NR/resveratrol or NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in muscle fiber phenotype, compared to those randomized to placebo.

  15. Physical activity (NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR alone improves physical activity at 6-month follow-up, compared to placebo.

  16. Physical activity (NR/Resveratrol vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR combined with resveratrol improves physical activity at 6-month follow-up, compared to placebo.


Other Outcome Measures:
  1. Walking Impairment Questionnaire (WIQ) speed and stair climbing score (NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR alone improves the WIQ speed and stair climbing score at 6-month follow-up, compared to placebo.

  2. Short-Form Physical Functioning (SF-36) score (NR alone vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR alone improves the WIQ speed and stair climbing scores and the Short-Form Physical Functioning score at 6-month follow-up, compared to placebo.

  3. Walking Impairment Questionnaire (WIQ) speed and stair climbing score (NR/resveratrol vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR combined with resveratrol improves the WIQ speed and stair climbing scores at 6-month follow-up, compared to placebo.

  4. Short-Form Physical Functioning (SF-36) score (NR/resveratrol vs. placebo) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR combined with resveratrol improves the Short-Form Physical Functioning score at 6-month follow-up, compared to placebo.

  5. Six-minute walk (NR/resveratrol vs. NR alone) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether those randomized to NR + resveratrol have greater improvement in the six-minute walk compared to those randomized to NR alone.

  6. Maximal treadmill walking time (NR/resveratrol vs. NR alone) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether those randomized to NR + resveratrol have greater improvement in maximal treadmill walking time compared to those randomized to NR alone.

  7. Walking Impairment Questionnaire (WIQ) distance score (NR/resveratrol vs. NR alone) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether those randomized to NR + resveratrol have greater improvement in the WIQ distance score compared to those randomized to NR alone.

  8. Physical activity (NR/Resveratrol vs. NR alone) [ Time Frame: Baseline to 6-month follow-up ]
    Among participants with PAD, we will determine whether NR/reseveratrol improves physical activity at 6-month follow-up, compared to NR alone.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

All participants will have PAD. PAD will be defined as an ankle-brachial index (ABI) <0.90 at the baseline study visit.

Exclusion Criteria:

  1. Above- or below-knee amputation.
  2. Critical limb ischemia.
  3. Wheelchair-bound or requiring a walker to ambulate.
  4. Walking is limited by a symptom other than PAD.
  5. Current foot ulcer on bottom of foot.
  6. End stage renal disease defined as a GFR less than 20 ml/min/1.73 M2.
  7. Significant liver impairment defined as two or more hepatic function enzymes >3.0 times the upper limit of normal. [NOTE: participants who meet this criterion may undergo a re-test of hepatic function tests to determine whether initially elevated hepatic enzymes represented a transient or spurious phenomenon.]
  8. Failure to successfully complete the 2-week study run-in.
  9. Planned lower extremity revascularization, orthopedic surgery, or other major surgery during the next six months.
  10. Lower extremity revascularization, orthopedic surgery, cardiovascular event, coronary revascularization, or other major surgery in the previous three months.
  11. Participation in supervised treadmill exercise during the previous three months.
  12. Major medical illness including renal disease requiring dialysis, lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who only use oxygen at night may still qualify.]
  13. Mini-Mental Status Examination (MMSE) score <23 or dementia.
  14. Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.]
  15. Currently taking study drug(s) or has taken study drug(s) in past six months.
  16. Increase in angina or angina at rest
  17. Non-English speaking.
  18. Visual impairment that limits walking ability.
  19. Women who are pregnant or who are pre-menopausal will not be eligible.
  20. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.

Potentially eligible participants will be advised that Medicare coverage for 12 weeks of supervised treadmill exercise is now available. Potential participants who have not participated in supervised treadmill exercise covered by Medicare and who desire to participate will be referred back to their physician for follow-up. These individuals may become eligible six months after they complete supervised treadmill exercise.

Vulnerable populations (fetuses, pregnant women, children, prisoners, and institutionalized persons) and adults unable to consent will not be included in the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03743636


Contacts
Layout table for location contacts
Contact: Mary M McDermott, MD 312-503-6419 mdm608@northwestern.edu
Contact: Kathryn Domanchuk, BS 3125036438 k-domanchuk@northwestern.edu

Locations
Layout table for location information
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Mary McDermott, MD    312-503-6419    mdm608@northwestern.edu   
Contact: Kathryn Domanchuk, BS    312-503-6438    k-domanchuk@northwestern.edu   
Principal Investigator: Mary McDermott, MD         
Sponsors and Collaborators
Northwestern University
American Heart Association
Investigators
Layout table for investigator information
Principal Investigator: Mary M McDermott, MD Northwestern University

Layout table for additonal information
Responsible Party: Mary McDermott, Professor of Medicine at Northwestern University Feinberg School of Medicine, Northwestern University
ClinicalTrials.gov Identifier: NCT03743636     History of Changes
Other Study ID Numbers: STU00206660
First Posted: November 16, 2018    Key Record Dates
Last Update Posted: November 16, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mary McDermott, Northwestern University:
Peripheral Artery Disease
PAD
Resveratrol
Nicotinamide riboside (NR)
Six-minute walk
Functional performance
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Peripheral Nervous System Agents
Atherosclerosis
Arteriosclerosis
Niacinamide
Niacin
Nicotinic Acids
Resveratrol
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Antimutagenic Agents
Anticarcinogenic Agents
Vitamin B Complex
Vitamins